MDNA Life Sciences Inc. (MDLS)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	51.95M
Revenue (ttm)	3.60M +3,298.1%
Net Income	-3.79M
EPS	-0.40
Shares Out	9.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About MDLS

MDNA Life Sciences is a life sciences company focused on the development of liquid biopsy tests based on the mitochondrial genome. We have discovered novel biomarkers and designed laboratory assays, which we refer to as our Mitomic Technology, that are intended to use mitochondrial DNA to detect cancer earlier, more accurately, and less invasively than traditional methods. Though we have no commercially available FDA or foreign regulator approved products, we have licensed our intellectual property related to the Mitomic prostate cancer biomark...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2002
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: MDLS
• Website: https://mdnalifesciences.com/

Financial Performance

Data Source: SEC filings Last updated: Sep 3, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error